ABSTRACT

Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives

This invention concerns compounds of formula



(I),

the *N*-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is CH or N; R^1 is hydrogen, C_{1-6}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, amino, mono- or di(C_{1-6}alkyl)amino, Ar^1, Ar^1NH-, C_{3-6}cycloalkyl, hydroxymethyl or benzyloxymethyl; R^2 is hydrogen, C_{1-6}alkyl, amino, aminocarbonyl, mono- or di(C_{1-6}alkyl)amino, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonylamino, hydroxy or C_{1-6}alkyloxy; R^3, R^4 and R^5 are each independently selected from hydrogen, halo, C_{1-6}alkyl, C_{1-6}alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkylthio, C_{1-6}alkyloxycarbonyl or Het^1; —(A)— is Ar^2, Ar^2CH_2- or Het^2; Ar^1 and Ar^2 optionally substituted phenyl; Het^1 and Het^2 are optionally substituted monocyclic heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.